Fri, Apr 25, 2014
A A A
Welcome sandeep.kottawar@wns.com
RSS

Sovereign Wealth Funds Briefing - Categorized | Investment

Temasek to up stake in South Korea’s Celltrion by $130 mln

Posted on 25 June 2013

South Korea’s Celltrion Inc said on Monday that Temasek, its key shareholder and Singapore’s sovereign wealth fund, has agreed to increase its stake in the biotech firm with an investment of about $130 million, as it awaits European approval of a key drug.
The deal comes after founder and Chief Executive Seo Jung-jin said in April that he would seek a buyer among multinational drugmakers for his controlling interest in the firm, once Remsima, a generic version of Merck & Co’s arthritis drug Remicade, is approved for sale in the European Union………………………………………..Full Article: Source


 Article link

This post was written by:

VRS - who has written 13926 posts on Opalesque Sovereign Wealth Funds Briefing.


Contact the author

Comments are closed.

banner
banner
April 2014
M T W T F S S
« Mar    
 123456
78910111213
14151617181920
21222324252627
282930